GLP-1s are not recommended for those who are breastfeeding
[28] A 2014 meta-analysis found no evidence for increased pancreatic cancer risk in people treated with DPP-4 inhibitors, but owing to the modest amount of data available, the authors were unable to completely exclude possibly increased risk
Farmacolgicamente, estos medicamentos funcionan mediante varios mecanismos integrados: Estimulacin de la secrecin de insulina dependiente de glucosa : Los agonistas GLP-1 aumentan la liberacin de insulina pancretica solo cuando los niveles de glucosa estn elevados, reduciendo el riesgo de hipoglucemia
doctors are prescribing them to children at unprecedented rates
Mol Metab 2014;3:507-17.ArticlePubMedPMC 23
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: BioMedWire Austin, Texas www.BioMedWire.com 512.354.7000 Office [email protected] BioMedWire is powered by IBN